France Dilated Cardiomyopathy Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The phrase "dilated cardiomyopathy" refers to conditions that affect the heart muscle and is regarded as a deadly cardiac condition. Reduced myocardial contractility and left and right ventricular dilatation are usually its defining characteristics. The potential driving force behind the DCM Therapeutics Market has been the rise in diagnostic alterations and symptom awareness, as well as declining dietary and lifestyle choices that have led to an increase in the occurrence of disease. The government is sponsoring research and development (R&D) projects to encourage scientists and pharmaceutical firms to create novel treatments. Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vericel Corporation, and many others are key players in the market for cystic fibrosis (CF) therapeutics.
France Dilated Cardiomyopathy Therapeutics Market is valued at around $0.8 Mn in 2022 and is projected to reach $0.92 Mn by 2030, exhibiting a CAGR of 1.7% during the forecast period 2023-2030.
The term "dilated cardiomyopathy" (DCM) describes the myocardium's weakness, consequent dilatation, and malfunction. Concomitant hypertrophy is typically present as well. The heart is typically enlarged and flabby in DCM. In DCM, there are no distinct histologic abnormalities. DCM has a variety of causes, including genetic factors (30 to 50% of cases), toxic factors (such as alcohol and chemotherapy drug doxorubicin), metabolic factors (such as iron overload in hereditary hemochromatosis), viral factors, and antecedent myocardial infarction. Nearly 20% of instances of DCM are caused by mutations in the TTN gene, which codes for the Titin protein. Dilated cardiomyopathy is frequently brought on by the Trypanosome cruzi-caused Chagas disease in Latin America.
The potential driving force behind the DCM Therapeutics Market has been the rise in diagnostic alterations and symptom awareness, as well as declining dietary and lifestyle choices that have led to an increase in the occurrence of disease. The government is sponsoring research and development (R&D) activities in an effort to encourage scientists and pharmaceutical businesses to create novel medications.
Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vericel Corporation, and many others are key players in the market for cystic fibrosis (CF) therapeutics.
Different diagnostic tests used to treat peripartum cardiomyopathy are increasing, which is helping the market's growth. To find the presence of particular abnormalities, various techniques are used, such as cardiac MRI and electrocardiography. As a result, it plays a key role in the market's expansion.
Increasing The market for DCM therapies is also being driven by the prevalence of DCM.
Changes in Lifestyle: Smoking is one of the top causes of preventable illness and death in the United States. Every year, it causes more than 480,000 deaths. Additionally, the modern population's adopted lifestyles that include an unhealthy way of living, a poor diet, stress, and many other similar problems all contribute to the market's expanding prospects.
An increase in research and development (R&D) activities: R&D activities are one factor boosting the market's growth. As a result, the market for dilated cardiomyopathy will benefit globally. The government is sponsoring research and development (R&D) projects to encourage scientists and pharmaceutical firms to create novel treatments. For instance, TN-301 (TYA-11631) is being developed to treat hereditary dilated cardiomyopathy and heart failure (HF) with preserved ejection fraction (HFpEF) (DCM). Oral administration is the method used. The potential medication works by inhibiting histone deacetylase 6. (HDAC6).
Development in Dilated Cardiomyopathy Therapeutics Market
For the treatment of hereditary dilated cardiomyopathy and heart failure (HF) with preserved ejection fraction (HFpEF), TN-301 (TYA-11631) is being developed (gDCM). Oral administration is the method used. The potential medication works by inhibiting histone deacetylase 6. (HDAC6).
In order to meet important clinical requirements for people with hereditary heart disease, MyoKardia is creating a pipeline of innovative small-molecule medicines. One million persons in the United States suffer from hypertrophic and dilated cardiomyopathy combined, and for which no innovative treatments have been made available in the market in more than ten years.
Preclinical AAV-based gene therapy programmes are being developed by Rocket Pharmaceuticals for the treatment of PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM).
Key playersNovartis Sanofi Gilead Sciences Abbott Laboratories Amgen Pfizer Bristol-Myers Squibb Johnson & Johnson Celgene Roche
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
22.214.171.124 Product Applications and Services
126.96.36.199 Recent Developments
188.8.131.52 Partnerships Ecosystem
184.108.40.206 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug class
By Route of Administration
By Distribution Channel
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses